tiprankstipranks
Trending News
More News >
Biotest (0N6Z) (DE:BIO)
:BIO

Biotest (BIO) AI Stock Analysis

Compare
4 Followers

Top Page

DE

Biotest

(LSE:BIO)

Rating:68Neutral
Price Target:
Biotest scores moderately due to a balanced financial performance and strength in technical indicators, offset by a high valuation. The stable balance sheet and improved cash flows are positive, but operational inefficiencies pose challenges. Technical analysis suggests bullish momentum, yet the high P/E ratio indicates potential overvaluation, balanced slightly by a strong dividend yield.

Biotest (BIO) vs. iShares MSCI Germany ETF (EWG)

Biotest Business Overview & Revenue Model

Company DescriptionBiotest AG is a Germany-based biotechnology company specializing in the development and production of plasma protein therapies and biotherapeutic drugs. The company operates primarily in the healthcare sector, focusing on products for clinical immunology, hematology, and intensive care medicine. Biotest's core products include immunoglobulins, clotting factors, and albumin solutions, which are used in treating various life-threatening diseases and conditions.
How the Company Makes MoneyBiotest generates revenue through the manufacturing and sale of plasma protein products and biotherapeutic drugs. The company's key revenue streams include sales of immunoglobulins, which are essential for patients with immune deficiencies; clotting factors used for treating hemophilia and other bleeding disorders; and albumin solutions used in intensive care settings. Biotest also engages in research and development activities aimed at expanding its product portfolio and improving existing therapies. Strategic partnerships and collaborations with other pharmaceutical and biotechnology firms can also contribute to its earnings by facilitating market expansion and distribution of its products.

Biotest Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
726.20M684.60M516.10M515.60M484.20M
Gross Profit
223.80M280.30M124.90M80.70M130.10M
EBIT
94.50M143.50M-13.00M-52.10M-13.20M
EBITDA
120.40M179.00M28.30M-17.70M16.00M
Net Income Common Stockholders
26.40M127.00M-31.60M-63.30M-31.40M
Balance SheetCash, Cash Equivalents and Short-Term Investments
119.50M118.50M136.60M117.50M89.20M
Total Assets
1.43B1.41B1.20B1.10B1.13B
Total Debt
597.20M689.80M574.30M496.30M469.10M
Net Debt
489.40M581.70M457.70M391.90M397.80M
Total Liabilities
903.30M912.00M831.90M723.80M689.70M
Stockholders Equity
530.70M498.90M371.10M380.40M441.60M
Cash FlowFree Cash Flow
32.20M-36.10M-69.80M15.70M-43.70M
Operating Cash Flow
60.90M-2.70M-40.50M33.90M-16.70M
Investing Cash Flow
-25.70M1.30M-37.00M-23.40M-14.60M
Financing Cash Flow
-35.40M-6.80M89.60M22.60M42.00M

Biotest Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price42.20
Price Trends
50DMA
42.50
Negative
100DMA
41.81
Positive
200DMA
41.70
Positive
Market Momentum
MACD
<0.01
Positive
RSI
41.65
Neutral
STOCH
30.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Neutral. The current price of 42.2 is below the 20-day moving average (MA) of 42.73, below the 50-day MA of 42.50, and above the 200-day MA of 41.70, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.65 is Neutral, neither overbought nor oversold. The STOCH value of 30.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:BIO.

Biotest Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
€311.17M20.382.99%5.62%-21.87%
DEEUZ
78
Outperform
€1.35B39.3317.48%0.08%15.89%14.62%
DEBIO
68
Neutral
€1.40B64.15-4.72%0.09%-18.82%-113.85%
DEFYB
63
Neutral
€484.01M5.89-26.06%-10.32%-250.76%
54
Neutral
$5.31B3.26-45.10%2.79%16.76%0.02%
DEEVT
49
Neutral
€1.25B-20.51%1.50%-127.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:BIO
Biotest
42.20
1.40
3.43%
DE:EVT
Evotec
7.16
-1.71
-19.30%
DE:EUZ
Eckert & Ziegler Strahlen und Medizintechnik
66.75
24.76
58.95%
DE:ILM1
Medios AG
12.02
-4.08
-25.34%
DE:FYB
Formycon AG
28.65
-19.85
-40.93%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.